To address this question, we validated eight plasma proteins (IL-17A, F5, FLT4, SFTPB, and GNPTG in lymphoma, TNFSF12, CCL3, and KIT in NSCLC) for response prediction and three plasma proteins (IL36G, SERPINC1, and LTA) for relapse monitoring. The gene discussed is TNFSF12; the disease is lymphoma.